Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aldeyra Therapeu (ALDX)

Aldeyra Therapeu (ALDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,400
  • Shares Outstanding, K 58,896
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,540 K
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade ALDX with:

Options Overview Details

View History
  • Implied Volatility 136.00% ( +50.13%)
  • Historical Volatility 77.95%
  • IV Percentile 77%
  • IV Rank 26.40%
  • IV High 374.83% on 10/26/23
  • IV Low 50.33% on 09/15/23
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,209
  • Volume Avg (30-Day) 470
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 9,015
  • Open Int (30-Day) 9,243

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate 0.02
  • Low Estimate -0.15
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +70.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +20.66%
on 03/15/24
4.34 -24.65%
on 03/01/24
-0.42 (-11.38%)
since 02/28/24
3-Month
2.71 +20.66%
on 03/15/24
4.34 -24.65%
on 03/01/24
-0.34 (-9.42%)
since 12/28/23
52-Week
1.42 +130.28%
on 10/16/23
11.97 -72.68%
on 06/15/23
-5.88 (-64.26%)
since 03/28/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:...

ALDX : 3.27 (+6.17%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) of a class action securities...

ALDX : 3.27 (+6.17%)
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...

ALDX : 3.27 (+6.17%)
Final Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit

/PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has...

ALDX : 3.27 (+6.17%)
ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between...

ALDX : 3.27 (+6.17%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:...

ALDX : 3.27 (+6.17%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) of a class action securities...

ALDX : 3.27 (+6.17%)
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

ALDX : 3.27 (+6.17%)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Aldeyra Investors of a Lead Plaintiff Deadline of September 29, 2023

/PRNewswire/ -- Attention Aldeyra Therapeutics, Inc. ("Aldeyra") (NASDAQ: ALDX) shareholders: The Law Offices of Vincent Wong announce that a class action...

ALDX : 3.27 (+6.17%)
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between...

ALDX : 3.27 (+6.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 3.85
2nd Resistance Point 3.68
1st Resistance Point 3.47
Last Price 3.27
1st Support Level 3.09
2nd Support Level 2.92
3rd Support Level 2.71

See More

52-Week High 11.97
Fibonacci 61.8% 7.94
Fibonacci 50% 6.70
Fibonacci 38.2% 5.45
Last Price 3.27
52-Week Low 1.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar